Literature DB >> 27965333

Nebulized epinephrine for young children with bronchiolitis.

Teeranai Sakulchit, Ran D Goldman.   

Abstract

QUESTION: Every winter I see infants with flulike symptoms and wheezing. I frequently diagnose them with bronchiolitis based on their presenting symptoms. Would it be prudent to send those infants to the nearest emergency department for treatment with nebulized epinephrine? ANSWER: Nebulized epinephrine should not be routinely used in infants with bronchiolitis. It is an option to consider in those with severe symptoms. If it is given and there are no signs of improvement, further doses are discouraged. Ongoing studies of epinephrine combined with other agents (eg, hypertonic saline, oral dexamethasone) are needed to confirm their benefit. Copyright© the College of Family Physicians of Canada.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27965333      PMCID: PMC5154648     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN: 0008-350X            Impact factor:   3.275


  18 in total

1.  A randomized, controlled trial of the effectiveness of nebulized therapy with epinephrine compared with albuterol and saline in infants hospitalized for acute viral bronchiolitis.

Authors:  Hema Patel; Robert W Platt; Gary S Pekeles; Francine M Ducharme
Journal:  J Pediatr       Date:  2002-12       Impact factor: 4.406

2.  The pharmacologic mechanism by which inhaled epinephrine reduces airway obstruction in respiratory syncytial virus-associated bronchiolitis.

Authors:  F E Barr; N R Patel; C J Newth
Journal:  J Pediatr       Date:  2000-05       Impact factor: 4.406

3.  Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis.

Authors:  Shawn L Ralston; Allan S Lieberthal; H Cody Meissner; Brian K Alverson; Jill E Baley; Anne M Gadomski; David W Johnson; Michael J Light; Nizar F Maraqa; Eneida A Mendonca; Kieran J Phelan; Joseph J Zorc; Danette Stanko-Lopp; Mark A Brown; Ian Nathanson; Elizabeth Rosenblum; Stephen Sayles; Sinsi Hernandez-Cancio
Journal:  Pediatrics       Date:  2014-11       Impact factor: 7.124

4.  Hypertonic saline for bronchiolitis in infants.

Authors:  Simran Grewal; Ran D Goldman
Journal:  Can Fam Physician       Date:  2015-06       Impact factor: 3.275

5.  A randomized, controlled trial of nebulized 5% hypertonic saline and mixed 5% hypertonic saline with epinephrine in bronchiolitis.

Authors:  Faten Tinsa; Sana Abdelkafi; Imen Bel Haj; Samia Hamouda; Ines Brini; Bechir Zouari; Khadija Boussetta
Journal:  Tunis Med       Date:  2014-11

6.  Bronchiolitis: Recommendations for diagnosis, monitoring and management of children one to 24 months of age.

Authors:  Jeremy N Friedman; Michael J Rieder; Jennifer M Walton
Journal:  Paediatr Child Health       Date:  2014-11       Impact factor: 2.253

7.  High volume normal saline alone is as effective as nebulized salbutamol-normal saline, epinephrine-normal saline, and 3% saline in mild bronchiolitis.

Authors:  Ayse Berna Anil; Murat Anil; Ayse Bircan Saglam; Nevin Cetin; Alkan Bal; Nejat Aksu
Journal:  Pediatr Pulmonol       Date:  2010-01

8.  Substantial variability in community respiratory syncytial virus season timing.

Authors:  James A Mullins; Ashley C Lamonte; Joseph S Bresee; Larry J Anderson
Journal:  Pediatr Infect Dis J       Date:  2003-10       Impact factor: 2.129

9.  Epinephrine Improves the Efficacy of Nebulized Hypertonic Saline in Moderate Bronchiolitis: A Randomised Clinical Trial.

Authors:  J Carlos Flores-González; Miguel A Matamala-Morillo; Patricia Rodríguez-Campoy; Juan J Pérez-Guerrero; Belén Serrano-Moyano; Paloma Comino-Vazquez; Encarnación Palma-Zambrano; Rocio Bulo-Concellón; Vanessa Santos-Sánchez; Alfonso M Lechuga-Sancho
Journal:  PLoS One       Date:  2015-11-17       Impact factor: 3.240

10.  Prospective multicenter study of the viral etiology of bronchiolitis in the emergency department.

Authors:  Jonathan M Mansbach; Alexander J McAdam; Sunday Clark; Paul D Hain; Robert G Flood; Uchechi Acholonu; Carlos A Camargo
Journal:  Acad Emerg Med       Date:  2008-02       Impact factor: 3.451

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.